Applications of 6-Chloro-9-(Tetrahydro-2-Pyranyl)-Purine in Industrial Manufacturing

As a specialized chemical manufacturer, we supply 6-Chloro-9-(Tetrahydro-2-Pyranyl)-Purine to established enterprises active in synthetic pharmaceuticals, contract research and manufacturing, fine chemicals, and API intermediate production. The following sections detail the principal industrial applications and integration of this raw material based on real-world downstream practices.

1. Active Pharmaceutical Ingredient (API) Intermediate Synthesis

Research-based and generic pharmaceutical manufacturers incorporate this compound as a core intermediate during purine-based API synthesis, particularly for antiviral and anticancer drugs. The material’s protected purine structure and chloro substituent enable selective ring modifications and nucleophilic substitution, improving overall process yields and purity. Downstream users deploy this intermediate in multi-step nucleoside analogue synthesis through carefully controlled glycosylation, halide exchange, and deprotection reactions carried out under GMP-compliant conditions.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients
• US FDA 21 CFR 210/211 (Current Good Manufacturing Practice for Finished Pharmaceuticals)
• European Pharmacopoeia monographs for purine derivatives where applicable
• ISO 9001:2015 quality management

Typical usage ratio

• Typically dosed at 1.1–1.3 equivalents per target API precursor. Adjust based on substrate reactivity and impurity profile management.

Downstream process integration

• Introduced after initial nucleobase assembly, serving as a protected chloro-purine source in mid-stage API synthesis. Re-entered after deprotection and further functionalization.

Final product types

• Nucleoside antiviral actives (e.g., acyclovir derivatives)
• Purine-based cancer therapeutics
• Custom small molecule APIs supplied to global pharma markets
• Complex bulk drug substances for finished pharmaceutical formulations

2. Custom Synthesis in Contract Research Organizations (CROs)

CROs and CDMOs use 6-Chloro-9-(Tetrahydro-2-Pyranyl)-Purine for rapid prototyping of nucleoside, nucleotide, and custom purine analogues. Researchers value the tetrahydro-2-pyranyl protecting group for its acid lability, enabling selective deprotection post-coupling. This allows precise timelines in medicinal chemistry libraries and SAR (Structure-Activity Relationship) investigations, facilitating new lead molecule discovery under strict client and project confidentiality.

Industry compliance standards

• OECD Principles of Good Laboratory Practice (GLP)
• ISO 17025 laboratory accreditation
• NIH guidelines for chemical research safety
• Chemical Manufacturers Association (CMA) Responsible Care® program

Typical usage ratio

• 0.9–1.5 molar equivalents per synthetic step, depending on route design and required purity safeguards for intermediate characterization.

Downstream process integration

• Dosed at the start of lead compound synthesis sequences. Enables late-stage functionalization with nucleophiles and swift removal of the THP group before analytical or bioassay workup.

Final product types

• Novel purine scaffolds for medicinal chemistry research
• SAR candidate molecules
• Synthetic standards for bioanalytical LC-MS calibration
• Intermediate reference substances for regulatory submissions

3. Fine Chemical Manufacturing for Diagnostic Reagents

Specialized fine chemical producers employ this purine derivative as a critical starting material in the production of modified nucleoside analogues used within diagnostic reagents, clinical test kits, and biochemical marker systems. Its chemical stability and selective reactivity under anhydrous and non-protic conditions enable downstream modification to enzyme substrates and colorimetric indicators for in vitro diagnostics, with strict requirements for trace impurity and lot uniformity.

Industry compliance standards

• ISO 13485:2016 (Medical Devices—Quality Management Systems for Diagnostic Manufacturers)
• US FDA 21 CFR 820 (Quality System Regulation for Medical Devices)
• REACH EU (Registration, Evaluation, Authorization of Chemicals) for non-pharma chemical reagents
• USP guidelines for analytical reagent purity

Typical usage ratio

• Utilized at 1.0–1.2 equivalents relative to protected sugar acceptors during nucleoside base coupling. Adjusted to optimize labeling efficiency and minimize side product levels.

Downstream process integration

• Activated in alkylation or coupling steps to attach to diagnostic sugar moieties or fluorescent tags. Deprotects after core conjugation.

Final product types

• Enzyme reagent substrates for in vitro diagnostics
• Fluorescent-labeled nucleoside markers for DNA quantification
• Colorimetric test kit chemicals
• Biochemical research reagents for central laboratory platforms

4. Nucleic Acid Chemistry and Oligonucleotide Synthesis

Producers of oligonucleotides and modified nucleic acids introduce this intermediate for site-selective purine assembly in synthetic RNA/DNA chains, crucial for antisense oligo, aptamer, and synthetic gene construction. Compatibility with automated solid-phase synthesis and cleavable protection meets the rigorous demands of clinical trial material, R&D, and commercial batch production, with full traceability and lot release documentation required by leading nucleic acid technology firms.

Industry compliance standards

• US Pharmacopeia (USP) monographs for nucleic acid substances
• GMP compliance for oligonucleotide APIs (as per FDA and EMA guidance)
• ISO 9001:2015 for global quality management
• Environmental, Health & Safety (EHS) controls under local regulatory authority

Typical usage ratio

• Inserted at 1.0 equivalent per cycle during solid-phase synthesis runs. May deviate ±0.1 eq. based on chain length, loading density, and steric factors.

Downstream process integration

• Loaded into the monomer supply vessel for stepwise nucleotide addition. THP deprotection occurs after chain elongation, prior to product purification.

Final product types

• Antisense oligonucleotides (ASOs) for gene modulation
• Aptamer molecules for therapeutic or analytical use
• Synthetic genes for industrial biotechnology
• Custom-labeled nucleic acid tools for molecular diagnostics